Cigna Move Offers More Good News For US Humira Biosimilars
As AbbVie Responds To Latest Gains Made By Adalimumab Rivals In Recent Weeks
Cigna’s Evernorth has announced plans to make a Humira biosimilar available for $0 out-of-pocket for Accredo patients from June, adding to momentum for adalimumab rivals from previous policy changes made by CVS in recent weeks. Meanwhile, AbbVie has offered the latest on how competition to its once top-selling brand is ramping up.
